Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | PRNP | P04156 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27974433 | 0.98 | LMNA (0.55) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL858150 | 0.84 | PDE4A (0.53) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL31236169 | 0.84 | PDE4A (0.53) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL7478867 | 0.82 | PDE4A (0.52) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL856909 | 0.79 | PDE4A (0.57) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL29793572 | 0.79 | PDE4A (0.57) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8021772 | 0.76 | HTT (0.57) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL6590076 | 0.76 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3106281 | 0.76 | HTT (0.53) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL2508850 | 0.76 | MAP4K4 (0.56) | LMNASMN1; SMN2ALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184650-A | 6- (1H-pyrrolo [2,3-b ] pyridin-3-yl) quinazoline-4-amine derivative, and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-06-14 | — | — | CN | claimed |
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-02-12 | — | — | US | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| EP-0520722-B1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LTD (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| EP-0520722-A1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | LMNA 2370/4885SMN1; SMN2 3953/4885ALDH1A1 4568/4885 |
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | PIK3CA, PI4KA, PDPK1 | LMNA 4024/4885SMN1; SMN2 4095/4885ALDH1A1 1640/4885 |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | RIPK1, RIPK2, RIPK4 | LMNA 2558/4885SMN1; SMN2 1758/4885ALDH1A1 4827/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | LMNA 1139/4885SMN1; SMN2 3418/4885ALDH1A1 409/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | LMNA 3314/4885SMN1; SMN2 4444/4885ALDH1A1 3824/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | LMNA 2921/4885SMN1; SMN2 1842/4885ALDH1A1 4801/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | LMNA 1772/4885SMN1; SMN2 4574/4885ALDH1A1 1206/4885 |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | LMNA 2370/4885SMN1; SMN2 3953/4885ALDH1A1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.